logo

For the Inventor, By the Inventor

New York, NY, United States of America

Molecular Insight Pharmaceuticals, Inc.


USPTO Granted Patents = 40



Trademarks = 2

Forward Citations = 505

Loading Chart...
Loading Chart...

20 inventors (with patents filed for the assignee):

goldMedal John W Babich (36 out of 58 patents)

silverMedal Craig N Zimmerman (24 out of 36 patents)

bronzeMedal John L Joyal (20 out of 20 patents)

4.  Kevin P Maresca (19 out of 21 patents)

5.  Genliang Lu (16 out of 28 patents)

6.  Shawn Hillier (11 out of 11 patents)

7.  John Marquis (6 out of 6 patents)

8.  Jian-cheng Wang (4 out of 4 patents)

9.  Jason Moss (2 out of 2 patents)

10.  Machinani Rao (2 out of 2 patents)

11.  David R Elmaleh (1 out of 91 patents)

12.  Robert N Hanson (1 out of 14 patents)

13.  Chris Barone (1 out of 1 patent)

14.  James Kronauge (1 out of 1 patent)

15.  Miles P Smith (1 out of 3 patents)


Core Competencies:
Radiopharmaceuticals
Radioimaging Agents
PSMA-Targeted Therapy
Heterodimers
Carbonic Anhydrase IX
Technetium Complexes
Rhenium Complexes
Dendrimers
Fatty Acid Imaging Agents
Prostate Cancer Treatment
Diagnostic Imaging
Polypharmacophoric Agents

40 patents:

1. 11840592 - Preparations of meta-iodobenzylguanidine and precursors thereof (2023-12-12),
2. 11712485 - Triazine based radiopharmaceuticals and radioimaging agents (2023-08-01),
3. 11279784 - Preparations of meta-iodobenzylguanidine and precursors thereof (2022-03-22),
4. 11167049 - Organ protection in PSMA-targeted radionuclide therapy of prostate cancer (2021-11-09),
5. 10898598 - Triazine based radiopharmaceuticals and radioimaging agents (2021-01-26),
6. 10668174 - Organ protection in PSMA-targeted radionuclide therapy of prostate cancer (2020-06-02),
7. 10647666 - Heterodimers of glutamic acid (2020-05-12),
8. 10640461 - Heterodimers of glutamic acid (2020-05-05),
9. 10201624 - Triazine based radiopharmaceuticals and radioimaging agents (2019-02-12),
10. 10131627 - Heterodimers of glutamic acid (2018-11-20),
11. 10086096 - Triazine based radiopharmaceuticals and radioimaging agents (2018-10-02),
12. 9956305 - Organ protection in PSMA-targeted radionuclide therapy of prostate cancer (2018-05-01),
13. 9878980 - Heterodimers of glutamic acid (2018-01-30),
14. 9687572 - PSMA-targeted dendrimers (2017-06-27),
15. 9447121 - Triazine based radiopharmaceuticals and radioimaging agents (2016-09-20),
Molecular Insight Pharmaceuticals is a leading precision medicine company focused on the discovery and development of innovative molecular imaging radiopharmaceuticals and targeted radiotherapeutics. Our mission is to improve patient outcomes by providing physicians with better tools to diagnose, stage, and monitor disease, and to select appropriate treatments based on individual patient biology. By harnessing the power of molecular imaging and targeted therapy, we aim to revolutionize cancer care and enhance the effectiveness of therapeutic interventions.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

40 Patents

#199 in New York, NY

#481 in New York

#8,349 in US

#16,567 in the World

...
New York, NY, United States of America

Molecular Insight Pharmaceuticals, Inc.

Forward Citations = 505

20 inventors:

goldMedal John W Babich (36 out of 58 patents)

silverMedal Craig N Zimmerman (24 out of 36 patents)

bronzeMedal John L Joyal (20 out of 20 patents)

4.  Kevin P Maresca (19 out of 21 patents)

5.  Genliang Lu (16 out of 28 patents)

Please report any incorrect information to support@idiyas.com
Loading…